HiberCell, a biotechnology company developing therapeutics for the prevention of cancer relapse and metastasis, closed on a $30 million debt facility with Hercules Capital. In addition, HiberCell completed a Series B financing round for gross proceeds of $67.4 million.
SCYNEXIS secured a $60 million term loan facility with Hercules Capital and Silicon Valley Bank. The capital strengthens SCYNEXIS’ balance sheet ahead of the anticipated commercial launch of Brexafemme, an oral antifungal product for the treatment of vaginal yeast infections.
Hercules Capital and Silicon Valley Bank provided a loan facility of up to $75 million for Geron, supporting the company with access to non-dilutive financial resources to support its imetelstat development program.
The U.S. Small Business Administration issued a “green light” or “go forth” letter inviting Hercules Capital to finalize its application process to obtain a license to form and operate a third small business investment company subsidiary.
Hercules Capital entered into a $100 million debt financing agreement with G1 Therapeutics, a clinical-stage oncology company. G1 plans to use the proceeds to fund commercialization and further development of trilaciclib.
Hercules Capital has replaced its existing $200 million credit facility with MUFG Union Bank with a new $400 million credit facility.
Urovant Sciences has entered into a $300 million term loan facility with Sumitomo Dainippon Pharma, a global Japanese pharmaceutical company.